{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:44:20Z","timestamp":1793681060462,"version":"4.5.1"},"reference-count":91,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec id=\"ab-yrv250007-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) therapies have revolutionized the management of chronic conditions like obesity and diabetes. Consistent with the overlap between feeding and metabolic pathways and those mediating addictive behaviors, growing evidence suggests that GLP-1 therapies may also be beneficial for treating alcohol and other substance use disorders (ASUDs). This review discusses the current landscape of GLP-1 therapies in the context of ASUDs, mental health considerations, and gaps and opportunities in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yrv250007-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Preclinical evidence across several experimental models and species consistently shows that GLP-1 receptor agonists (GLP-1RAs) reduce drug intake and other addictive behaviors. Research to date has primarily focused on alcohol; however, nicotine, opioids, and psychostimulants have also been studied. Observational cohort studies using electronic health records suggest improvements in ASUD-related outcomes among people treated with GLP-1RAs for other indications. Randomized clinical trials (RCTs) have been limited, yielding mixed results but overall promising signals. Several RCTs are ongoing or about to start. Despite some early pharmacovigilance alarms, GLP-1RAs do not seem to cause or increase the risk of psychopathology (eg, depression, suicidal ideation and\/or behavior). Some recent studies suggest beneficial effects of GLP-1RAs on mental health outcomes, but more work is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yrv250007-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The rationale for studying GLP-1 therapies for ASUDs is supported by preclinical and observational clinical evidence. RCTs are emerging and critically needed at this juncture to determine the safety and efficacy of GLP-1 therapies in people with ASUDs. Pending results from RCTs, GLP-1 therapies have the potential to be repurposed for ASUDs. However, there are several relevant questions in need of further investigation, including the specifics of treatment with GLP-1 therapies in the context of addiction (eg, dose, duration, tachyphylaxis, impact of discontinuation), individual differences and potential predictors of response, mechanisms of action, intersection with mental health and medical comorbidities, cost, and fair access to these treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.4308","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:49Z","timestamp":1769011249000},"page":"306","source":"Crossref","is-referenced-by-count":25,"title":["Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities\u2014Quo Vadis?"],"prefix":"10.1001","volume":"83","author":[{"given":"Mehdi","family":"Farokhnia","sequence":"first","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland"},{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland"},{"name":"Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island"},{"name":"Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"Department of Neuroscience, Georgetown University Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yrv250007r1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide-1.","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"8","key":"yrv250007r2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity, and beyond.","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"yrv250007r3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"yrv250007r4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation.","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"issue":"6741","key":"yrv250007r5","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0773","article-title":"Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.","volume":"387","author":"Zhu","year":"2025","journal-title":"Science"},{"issue":"1","key":"yrv250007r6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps.","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes Rev"},{"issue":"11","key":"yrv250007r7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.neuron.2025.03.010","article-title":"The neurobiology of overeating.","volume":"113","author":"Stuber","year":"2025","journal-title":"Neuron"},{"issue":"12","key":"yrv250007r8","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1038\/s41380-025-03259-8","article-title":"Crosstalk between alcohol use disorder and obesity: 2 sides of the same coin?","volume":"30","author":"Leggio","year":"2025","journal-title":"Mol Psychiatry"},{"key":"yrv250007r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target.","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"issue":"11","key":"yrv250007r10","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives.","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"yrv250007r11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series.","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"yrv250007r12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach.","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"issue":"1","key":"yrv250007r13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15288\/jsad.23-00318","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide-1 (GLP-1) receptor agonists for substance use disorders.","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"yrv250007r14","doi-asserted-by":"publisher","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity.","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"yrv250007r15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists.","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"yrv250007r16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events: a nationwide register-based cohort and self-controlled case series study.","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"yrv250007r17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder.","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yrv250007r18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis.","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"issue":"3","key":"yrv250007r19","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/dom.16152","article-title":"Glucagon-like peptide-1 analogues reduce alcohol intake.","volume":"27","author":"O\u2019Farrell","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"yrv250007r20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"issue":"1","key":"yrv250007r21","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"yrv250007r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsgos.2025.100659","article-title":"Glucagon-like peptide-1 receptor agonists and alcohol use: a real-world observational study in a large, integrated health care system.","author":"Palzes","journal-title":"Biol Psychiat-Glob O"},{"key":"yrv250007r23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats.","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"issue":"8","key":"yrv250007r24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data.","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"yrv250007r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-Month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"9","key":"yrv250007r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"yrv250007r27","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70024","article-title":"GLP-1 receptor agonists and substance use disorders in older adults with type 2 diabetes: a target trial emulation.","author":"Dai","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"yrv250007r28","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"19","key":"yrv250007r29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"yrv250007r30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial.","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"yrv250007r31","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce postcessation weight gain: a pilot randomized controlled trial.","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"yrv250007r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-center, randomized, double-blind, placebo-controlled, parallel group trial.","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"eClinMed"},{"key":"yrv250007r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"22","key":"yrv250007r34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation.","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"yrv250007r35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000481348","article-title":"Reduced drinking in alcohol dependence treatment, what is the evidence?","volume":"23","author":"Mann","year":"2017","journal-title":"Eur Addict Res"},{"issue":"11","key":"yrv250007r36","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/acer.13884","article-title":"Reduction in nonabstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT-C scores: prospective 3-year follow-up results in the US general population.","volume":"42","author":"Knox","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"yrv250007r37","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/acer.14386","article-title":"Reduction in world health organization risk drinking levels and cardiovascular disease.","volume":"44","author":"Knox","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"yrv250007r38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/ADM.0000000000001303","article-title":"Reductions in World Health Organization risk drinking level are associated with reductions in alcohol use disorder diagnosis and criteria: evidence from an alcohol pharmacotherapy trial.","volume":"18","author":"Richards","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"yrv250007r39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40290-024-00526-x","article-title":"End points for pharmacotherapy trials for alcohol use disorder.","volume":"38","author":"Belnap","year":"2024","journal-title":"Pharmaceut Med"},{"issue":"11","key":"yrv250007r40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172889","article-title":"Novel medications for problematic alcohol use.","volume":"134","author":"Heilig","year":"2024","journal-title":"J Clin Invest"},{"issue":"9","key":"yrv250007r42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/oby.21582","article-title":"The effect of tobacco cessation on weight gain, obesity, and diabetes risk.","volume":"24","author":"Bush","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"yrv250007r43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1803626","article-title":"Smoking cessation, weight change, type 2 diabetes, and mortality.","volume":"379","author":"Hu","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"yrv250007r44","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation.","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"yrv250007r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-center, randomized, double-blind, placebo-controlled, parallel group trial.","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"eClinMed"},{"issue":"8","key":"yrv250007r46","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis.","volume":"26","author":"Berg","year":"2025","journal-title":"Obes Rev"},{"issue":"1","key":"yrv250007r47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13722-024-00481-7","article-title":"Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.","volume":"19","author":"Freet","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"12","key":"yrv250007r49","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"yrv250007r50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment.","volume":"120","author":"Volkow","year":"2025","journal-title":"Addiction"},{"issue":"10497","key":"yrv250007r51","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/S0140-6736(25)01012-8","article-title":"Understanding the drivers and consequences of early-onset type 2 diabetes.","volume":"405","author":"Lim","year":"2025","journal-title":"Lancet"},{"issue":"suppl 2","key":"yrv250007r52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","article-title":"An overview of obesity-related complications: the epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.","volume":"27 suppl 2","author":"Bl\u00fcher","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"yrv250007r53","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/432607","article-title":"Rimonabant: from RIO to ban.","volume":"2011","author":"Sam","year":"2011","journal-title":"J Obes"},{"issue":"11","key":"yrv250007r54","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials.","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"yrv250007r55","doi-asserted-by":"publisher","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality.","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"yrv250007r56","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s11096-025-01943-x","article-title":"Psychiatric adverse events linked to glucagon-like peptide-1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.","volume":"47","author":"Katranski","year":"2025","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"yrv250007r57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"yrv250007r58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2025-301635","article-title":"Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study.","volume":"28","author":"Peng","year":"2025","journal-title":"BMJ Ment Health"},{"issue":"1","key":"yrv250007r59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"yrv250007r60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668765","article-title":"Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances.","volume":"12","author":"Khouri","year":"2021","journal-title":"Front Pharmacol"},{"key":"yrv250007r61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"GLP-1 agonists and risk of suicidal thoughts and behaviours\u2014confound by indication once again: a narrative review.","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"yrv250007r62","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12676","article-title":"Glucagon-like peptide-1 receptor agonism and attempted suicide: a mendelian randomization study to assess a potential causal association.","volume":"14","author":"Nguyen","year":"2024","journal-title":"Clin Obes"},{"issue":"12","key":"yrv250007r63","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035948","article-title":"Glucagon-like peptide-1 receptor agonism and suicide risk: evidence from mendelian randomization.","volume":"13","author":"Zhao","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"yrv250007r64","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials.","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"10","key":"yrv250007r65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023830","article-title":"Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.","volume":"8","author":"Gamble","year":"2018","journal-title":"BMJ Open"},{"issue":"8","key":"yrv250007r66","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7326\/M24-0329","article-title":"Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in US older adults with type 2 diabetes: a target trial emulation study.","volume":"177","author":"Tang","year":"2024","journal-title":"Ann Intern Med"},{"issue":"6","key":"yrv250007r67","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15538","article-title":"Glucagon-like peptide-1 receptor agonists and mental health: a meta-analysis of randomized controlled trials.","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"yrv250007r68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide-1 receptor agonists and mental health: a systematic review and meta-analysis.","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"yrv250007r69","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis.","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"yrv250007r70","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpsychires.2025.02.008","article-title":"The effect of glucagon-like peptide-1 receptor agonists on measures of suicidality: a systematic review.","volume":"183","author":"Valentino","year":"2025","journal-title":"J Psychiatr Res"},{"issue":"4","key":"yrv250007r71","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2025.103238","article-title":"Glucagon-like peptide-1 receptor agonists, dual GIP\/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review of clinical studies and pharmacovigilance reports.","volume":"19","author":"Di Stefano","year":"2025","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"yrv250007r72","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70037","article-title":"Association of GLP-1 receptor agonists with risk of suicidal ideation and behaviour: a systematic review and meta-analysis.","volume":"41","author":"Bushi","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"yrv250007r73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100333","article-title":"GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa): a systematic review.","volume":"35","author":"Aoun","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"yrv250007r74","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: a systematic review.","volume":"11","author":"Tempia Valenta","year":"2024","journal-title":"Curr Treat Options Psychiatry"},{"issue":"3","key":"yrv250007r75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders.","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"},{"key":"yrv250007r76","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2025.4","article-title":"Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.","volume":"37","author":"Au","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"yrv250007r77","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102343","article-title":"Type 2 diabetes mellitus\/obesity drugs: a neurodegenerative disorders savior or a bridge too far?","volume":"98","author":"Kopp","year":"2024","journal-title":"Ageing Res Rev"},{"key":"yrv250007r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion, and mood: a review.","volume":"110","author":"Guerrero-Hreins","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"yrv250007r79","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104615","article-title":"Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure.","volume":"152","author":"Yoon","year":"2020","journal-title":"Pharmacol Res"},{"issue":"12","key":"yrv250007r80","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP-1 receptor agonists.","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"1","key":"yrv250007r81","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"yrv250007r82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis.","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"yrv250007r83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119509","article-title":"Association of glucagon-like peptide-1 receptor agonists and 7 common mental disorders: a drug target and mediation mendelian randomization.","volume":"388","author":"Zhang","year":"2025","journal-title":"J Affect Disord"},{"issue":"11","key":"yrv250007r84","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11920-023-01458-0","article-title":"Antipsychotic-induced weight gain in severe mental illness: risk factors and special considerations.","volume":"25","author":"Stogios","year":"2023","journal-title":"Curr Psychiatry Rep"},{"key":"yrv250007r85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.","volume":"78","author":"Lee","year":"2022","journal-title":"Gen Hosp Psychiatry"},{"key":"yrv250007r86","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1153648","article-title":"Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.","volume":"14","author":"Khaity","year":"2023","journal-title":"Front Psychiatry"},{"issue":"3","key":"yrv250007r87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardiometabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials.","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"yrv250007r88","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000531","article-title":"A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.","author":"Menon","journal-title":"CNS Spectr"},{"issue":"6","key":"yrv250007r89","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis.","volume":"150","author":"Bak","year":"2024","journal-title":"Acta Psychiatr Scand"},{"key":"yrv250007r41","unstructured":"US Food and Drug Administration. FDA qualifies drug development tool to facilitate clinical trial research on alcohol use disorder. Accessed September 30, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-qualifies-drug-development-tool-facilitate-clinical-trial-research-alcohol-use-disorder"},{"key":"yrv250007r48","unstructured":"Appenzeller? T. Obesity drug cuts opiate craving. Accessed September 30, 2025. https:\/\/www.science.org\/content\/article\/obesity-drug-cuts-opiate-craving"},{"key":"yrv250007r90","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. Accessed September 30, 2025. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024"},{"key":"yrv250007r91","unstructured":"US Food and Drug Administration. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Accessed September 30, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2843977\/jamapsychiatry_farokhnia_2026_rv_250007_1772546823.75624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:00:24Z","timestamp":1772640024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2843977"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4308","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}